Coverage Highlights

8.1.14 Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research.
7.30.14 The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online.
November 2013 FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology.
11.20.13 FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured.
November-December 2013 Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189.
October 2013 Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.”
8.28.13 FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial.
5.30.13 Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.”
9.13.12 MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury.

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

News Coverage


  • ALS Stem Cell Therapy: Too Soon to Tell

By John Gever, MedPage Today, October 15, 2013

NSI-566/ALS Principal Investigator, Dr. Eva Feldman’s, presentation of Phase I data at the American Neurological Association annual meeting, is reported in this article which cites the three of 15 Phase I patients “receiving the most extensive injections showed stabilization of functional scores after almost 2 years of follow-up.”

View Article

  • P2P MDA Night of Hope

By Jocelyn Dorsey, WSB-TV Atlanta, October 16, 2013

NSI-566/ALS Phase I patient #12, Edward Tessaro’s, story with ALS is spotlighted on the eve of the 8th Annual MDA-ALS Night of Hope benefit in Atlanta. Site Principal Investigator, Emory’s Dr. Jonathan D. Glass, is also interviewed in this segment which includes surgery footage of the cell therapy treatment using Neuralstem’s proprietary breakthrough medical devices, the Spinal Platform and Floating Cannula.

View Segment

  • ALS stem cell trial begins at U-M Health System with first two patients receiving injections

By University of Michigan Health System, October 9, 2013

The first two NSI-566/ALS patients to be treated at the University of Michigan Health System and the Phase II trial are the focus of this article that also introduces Parag Patil, MD, PhD, the U-M neurosurgeon and biomedical engineer, who performed the surgeries. Dr. Patil is an engineering consultant to Neuralstem to further develop its proprietary cell therapy-delivery device.

View Article

  • Phase II of ALS stem cell trial underway at Emory and University of Michigan

By Janet Christenbury, Woodruff Health Sciences Center, Emory University, October 3, 2013

Emory’s NSI-566/ALS Site Principal Investigator, Jonathan D. Glass, MD, and Co-Investigator and Neurosurgeon Nicholas M. Boulis, MD, who designed Neuralstem’s proprietary, patented spinal platform and floating cannula specifically for the world’s first delivery of cells directly into the gray matter of the spinal cord, are interviewed about the Phase II trial now underway.

View Article

  • ALS patient walking, showing improvement after stem cell treatment

By Deena Centofanti, FOX News Detroit, August 28, 2013

FOX News Detroit’s Deena Centofanti speaks with NSI-566/ALS Principal Investigator Eva Feldman, MD, PhD, and Phase I patient, Ted Harada, in a “Health Works” feature on Neuralstem’s “landmark study” with collaborators at the University of Michigan and Emory University, on the eve of the Phase II trial.

View Segment

Privacy and Terms ©Neuralstem, Inc. 2016